Full Value of Vaccines Assessment for Invasive Non-Typhoidal Salmonella Vaccines

Every year, invasive non-typhoidal *Salmonella* (iNTS) kills tens of thousands of people in sub-Saharan Africa, yet no vaccine exists to stop it. This project aims to change that by building the economic and public-health case for developing an iNTS vaccine. Currently, several candidate vaccines are in the pipeline—some targeting two common strains, others combining iNTS with typhoid—but without a clear justification for investment, pharmaceutical companies and global health funders have little incentive to push them through to licensure. The research team, led by the International Vaccine Institute and the World Health Organization, will produce a Full Value of Vaccines Assessment (FVVA). This is a detailed document that lays out the preferred vaccine characteristics, a research and development roadmap, a business case, and a regulatory pathway. If the FVVA succeeds in making the financial and health arguments compelling, the result could be a safe, effective iNTS vaccine reaching the children and immunocompromised adults who need it most. That would mean WHO policy recommendations, Gavi financing, UNICEF procurement, and ultimately, routine immunisation in the countries where iNTS is a persistent killer. The work is not fundamental science—it is a deliberate, strategic push to turn promising candidates into a real-world public health tool.